Disease · MONDO_0011786
Comparisons in its trials40
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 40
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Astepro Nasal Spray vs Astelin Nasal Spray: Number of Participants Reporting Adverse Events | 207 of 428 | 211 of 430 | 858 | NCT00783432 | Trial comparisons |
| 5-mg Desloratadine Tablet vs Placebo Tablet: serious adverse events | 1 of 360 | 2 of 356 | 716 | NCT00405964 | Trial comparisons |
| Phenylephrine HCl ER, 30 mg vs Phenylephrine HCl IR, 10 mg: serious adverse events | 0 of 327 | 0 of 324 | 651 | NCT00976209 | Trial comparisons |
| Ciclesonide vs Mometasone: The Number of Subjects Experiencing AEs | 90 of 311 | 67 of 312 | 623 | NCT01401465 | Trial comparisons |
| Ciclesonide vs Mometasone: The Number of Subjects Experiencing Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation | 6 of 311 | 4 of 312 | 623 | NCT01401465 | Trial comparisons |
| Ciclesonide vs Mometasone: serious adverse events | 0 of 311 | 2 of 312 | 623 | NCT01401465 | Trial comparisons |
| FF 110 µg vs MF 200 µg: serious adverse events | 0 of 298 | 0 of 298 | 596 | NCT02397915 | Trial comparisons |
| REGN1908-1909 vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study | 2 of 224 | 2 of 222 | 446 | NCT04981717 | Trial comparisons |
| REGN1908-1909 vs Placebo: Number of Participants With Adverse Event of Special Interests (AESIs) Throughout the Study | 2 of 224 | 0 of 222 | 446 | NCT04981717 | Trial comparisons |
| REGN1908-1909 vs Placebo: Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs) Throughout the Study | 2 of 224 | 2 of 222 | 446 | NCT04981717 | Trial comparisons |
| R1908-1909 600 mg vs Placebo: deaths from any cause | 0 of 218 | 0 of 222 | 440 | NCT04981717 | Trial comparisons |
| R1908-1909 600 mg vs Placebo: serious adverse events | 2 of 218 | 2 of 222 | 440 | NCT04981717 | Trial comparisons |
| REGN1908-1909 vs Placebo: Incidence of Treatment-emergent ADAs to REGN1909 Throughout the Study | 5 of 210 | 5 of 213 | 423 | NCT04981717 | Trial comparisons |
| REGN1908-1909 vs Placebo: Incidence of Treatment-emergent Anti-drug Antibodies (ADAs) to REGN1908 Throughout the Study | 6 of 210 | 4 of 213 | 423 | NCT04981717 | Trial comparisons |
| Dymista Nasal Spray vs Fluticasone Propionate Nasal Spray: serious adverse events | 1 of 304 | 0 of 101 | 405 | NCT01794741 | Trial comparisons |
| FFNS 110 mcg vs Placebo: serious adverse events | 0 of 181 | 0 of 182 | 363 | NCT01231464 | Trial comparisons |
| Ciclesonide vs Mometasone: serious adverse events | 0 of 175 | 0 of 176 | 351 | NCT01287364 | Trial comparisons |
| BDP HFA 320 µg/Day vs Placebo: serious adverse events | 1 of 167 | 0 of 171 | 338 | NCT01024608 | Trial comparisons |
| MFNS vs Placebo: serious adverse events | 0 of 220 | 0 of 113 | 333 | NCT01135134 | Trial comparisons |
| Fluticasone Furoate 55 µg Per Day vs Placebo: serious adverse events | 0 of 131 | 0 of 130 | 261 | NCT01630135 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011786/comparisons